Physician profile
Michael B Wright
NPI 1174753453
$2,746.75
in general payments reported to CMS, 2019-2025
19 companies · $674 in 2025
The $674 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $84.28 · 2021: $433 · 2022: $354 · 2023: $534 · 2024: $213 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,047.08 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $226.71 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $220.76 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $213.74 | 2019-2025 | Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.10 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $145.23 | 2025 | Auvelity |
| Alkermes, INC. | $139.44 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $101.44 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $79.64 | 2019-2024 | Rexulti |
| Allergan, INC. | $72.14 | 2019-2020 | |
| Indivior INC. | $67.87 | 2022-2023 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $49.95 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $47.07 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $43.13 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $40.59 | 2022-2025 | Xelstrym, Secuado |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.51 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $16.02 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.88 | 2025 | Jornay Pm |
| Rhodes Pharmaceuticals L.P. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.